(VIANEWS) – Shares of TherapeuticsMD (NASDAQ: TXMD) slid by a staggering 27.71% in 21 sessions from $6.17 at 2022-11-10, to $4.46 at 20:01 EST on Sunday, after two successive sessions in a row of gains. NASDAQ is sliding 0.52% to $11,226.36, following the last session’s downward trend.
TherapeuticsMD’s last close was $4.46, 88.42% below its 52-week high of $38.50.
TherapeuticsMD, Inc. is a United States women’s health company. The company provides IMVEXXY, a treatment for moderate-to severe dyspareunia, and BIJUVA which is a bioidentical hormonal therapy combination of 17ss -estradiol, and progesterone to treat moderate-to–severe vasomotor conditions. TX-015HR is a transdermal progesterone cream. TX-016HR is an estradiol-progesterone cream. TX-018HR contains an estradiol-progesterone cream. TX-017HR and TX-018HR are potential transdermal patches. TX-019HR includes an oral progesterone/estradiol formula. The company also produces and distributes generic and branded prescription prenatal vitamins, under the vitaTrue and vitaMedMD brands. It sells prescription drugs and prenatal vitamins to retail pharmacie distributors as well wholesale distributors. TherapeuticsMD, Inc., was established in Boca Raton, Florida in 2008.
Earnings per Share
TherapeuticsMD’s trailing 12 months profit per share is $-0.666
TherapeuticsMD’s current reported volume is currently 36956, which is 49.04% lower than its average volume (71804).
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 44.7% and 89.6%, respectively.
More news about TherapeuticsMD (TXMD).